Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100737 · ClinicalTrials.gov registry record · Phase 2
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
A Phase 2 study, sponsored by Chiron Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00100737 is a Phase 2 study that was terminated before completion, run by Chiron Corporation. The registered enrollment target is 300 participants.
The verdict
NCT00100737, a Phase 2 study, was terminated before completion, sponsored by Chiron Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.
Interventions
- DRUG rituximab
- DRUG interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100737
The ClinicalTrials.gov registry entry for NCT00100737 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiron Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00100737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100737 about?
NCT00100737 is a clinical study titled "Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)". The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory...
What is the current status of trial NCT00100737?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 300 participants.
What interventions are being tested in trial NCT00100737?
The interventions under investigation include: rituximab (DRUG), interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00100737?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.